KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Deferred Taxes (2021 - 2023)

Moderna (MRNA) has disclosed Deferred Taxes for 3 consecutive years, with -$106.0 million as the latest value for Q4 2023.

  • Quarterly Deferred Taxes fell 23.26% to -$106.0 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was -$106.0 million through Sep 2024, down 112.5% year-over-year, with the annual reading at $828.0 million for FY2023, 248.12% up from the prior year.
  • Deferred Taxes for Q4 2023 was -$106.0 million at Moderna, down from $1.5 billion in the prior quarter.
  • The five-year high for Deferred Taxes was $1.5 billion in Q3 2023, with the low at -$310.0 million in Q1 2023.
  • Average Deferred Taxes over 3 years is -$4.1 million, with a median of -$101.5 million recorded in 2022.
  • The sharpest move saw Deferred Taxes crashed 945.45% in 2022, then skyrocketed 1609.28% in 2023.
  • Over 3 years, Deferred Taxes stood at -$229.0 million in 2021, then surged by 62.45% to -$86.0 million in 2022, then decreased by 23.26% to -$106.0 million in 2023.
  • According to Business Quant data, Deferred Taxes over the past three periods came in at -$106.0 million, $1.5 billion, and -$220.0 million for Q4 2023, Q3 2023, and Q2 2023 respectively.